Better Assess Urogenital Cancers with UroGenRA®
UroGenRA®, CGI’s custom oligonucleotide array product line, is designed to detect genomic copy number alterations (CNA) with prognostic and diagnostic value in kidney, prostate and bladder cancers. It was designed to detect gains and losses that frequently occur in genetic material in these three cancer types and has the potential to differentially diagnose and/or stratify patients to assist in and guide clinical management. The first application of UroGenRA® Array-CGH, UroGenRA®-Kidney is both CLIA and New York State approved.
UroGenRA®-Kidney is specifically designed to classify renal tumors into the three major malignant subtypes: clear cell renal cell carcinoma (ccRCC), papillary RCC (pRCC), chromophobe RCC (chrRCC), and one benign: oncocytoma (OC), which is critical to patient management and treatment protocols.
Especially in cases where there is limited biopsy material, UroGenRA®-Kidney allows clinicians to diagnose renal cancer and accurately classify it into the correct subtype, provide rationale for selection among surgical and non-surgical intervention or ablation, stratify patients based on prognostic information for the advancement of renal cancer into local or regional cancer which then guides decisions on surgical intervention, and guide drug trial decisions in those with metastatic disease or “unclassified” renal cancers.
By histology alone over 15% of needle biopsies of renal masses are rendered non-diagnostic and about 4-6% of surgically-resected specimens are unclassifiable. RCC subtypes are characterized by well-known genomic alterations which can be utilized for classification purposes. These differential genomic alterations are assayed in the current test by array comparative genomic hybridization (array-CGH) to classify both needle biopsies and surgically-resected renal specimens. UroGenRA®-Kidney can be useful in assisting histology for accurate classification of RCC.